Brokerages expect Genpact Limited (NYSE:G) to report $721.69 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Genpact’s earnings, with estimates ranging from $717.82 million to $728.30 million. Genpact posted sales of $681.75 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.9%. The firm is scheduled to announce its next quarterly earnings results after the market closes on Monday, February 12th.
According to Zacks, analysts expect that Genpact will report full year sales of $721.69 million for the current year, with estimates ranging from $2.70 billion to $2.73 billion. For the next fiscal year, analysts forecast that the business will report sales of $2.89 billion per share, with estimates ranging from $2.85 billion to $2.95 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Genpact.
Several research analysts have commented on the company. Robert W. Baird reaffirmed a “buy” rating and set a $38.00 price target on shares of Genpact in a research report on Friday, November 10th. Cowen reiterated a “buy” rating and set a $33.00 price target on shares of Genpact in a research report on Thursday, October 12th. SunTrust Banks reiterated a “buy” rating and set a $34.00 price target on shares of Genpact in a research report on Monday, October 9th. Zacks Investment Research upgraded shares of Genpact from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research report on Friday, November 10th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $36.00 price target on shares of Genpact in a research report on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $33.38.
In other Genpact news, insider Piyush Mehta sold 17,017 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $31.00, for a total value of $527,527.00. Following the sale, the insider now owns 82,461 shares in the company, valued at $2,556,291. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Arvinder Singh sold 22,855 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $32.23, for a total transaction of $736,616.65. Following the completion of the sale, the senior vice president now owns 37,623 shares in the company, valued at approximately $1,212,589.29. The disclosure for this sale can be found here. Insiders sold 1,654,797 shares of company stock worth $50,356,184 in the last 90 days. Company insiders own 1.41% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in Genpact by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 6,508 shares of the business services provider’s stock worth $181,000 after buying an additional 455 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Genpact by 3.1% in the second quarter. Ameriprise Financial Inc. now owns 30,196 shares of the business services provider’s stock valued at $840,000 after purchasing an additional 907 shares in the last quarter. Sit Investment Associates Inc. increased its stake in Genpact by 4.5% in the fourth quarter. Sit Investment Associates Inc. now owns 37,100 shares of the business services provider’s stock valued at $1,178,000 after purchasing an additional 1,590 shares in the last quarter. FDx Advisors Inc. increased its stake in Genpact by 2.9% in the third quarter. FDx Advisors Inc. now owns 61,488 shares of the business services provider’s stock valued at $1,768,000 after purchasing an additional 1,713 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Genpact by 12.4% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 16,466 shares of the business services provider’s stock valued at $473,000 after purchasing an additional 1,816 shares in the last quarter. 91.48% of the stock is owned by hedge funds and other institutional investors.
Genpact (G) traded down $0.86 on Thursday, reaching $33.32. The company’s stock had a trading volume of 673,588 shares, compared to its average volume of 717,408. The firm has a market capitalization of $6,432.16, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 2.07 and a beta of 0.57. Genpact has a 52 week low of $23.34 and a 52 week high of $34.79. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.65 and a current ratio of 1.65.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Genpact Limited (G) Will Announce Quarterly Sales of $721.69 Million” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/04/zacks-brokerages-anticipate-genpact-limited-g-will-announce-quarterly-sales-of-721-69-million.html.
Genpact Limited is engaged in providing digitally powered business process management and services. The Company is also engaged in designing, transforming and running a combination of processes, as well as providing solutions that combine elements of its service offerings. The Company’s segments include Business process outsourcing and Information technology services.
Get a free copy of the Zacks research report on Genpact (G)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genpact Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genpact and related companies with MarketBeat.com's FREE daily email newsletter.